IBDEI08H ; ; 09-MAY-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 09, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11286,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11286,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,11286,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,11286,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,11287,0)
 ;;=204.00^^69^691^2
 ;;^UTILITY(U,$J,358.3,11287,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11287,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,11287,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,11287,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,11288,0)
 ;;=204.01^^69^691^1
 ;;^UTILITY(U,$J,358.3,11288,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11288,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,11288,1,5,0)
 ;;=5^ALL in Remission
 ;;^UTILITY(U,$J,358.3,11288,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,11289,0)
 ;;=204.10^^69^691^26
 ;;^UTILITY(U,$J,358.3,11289,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11289,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,11289,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,11289,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,11290,0)
 ;;=204.11^^69^691^24
 ;;^UTILITY(U,$J,358.3,11290,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11290,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,11290,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,11290,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,11291,0)
 ;;=202.41^^69^691^73
 ;;^UTILITY(U,$J,358.3,11291,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11291,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,11291,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,11291,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,11292,0)
 ;;=201.90^^69^691^80
 ;;^UTILITY(U,$J,358.3,11292,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11292,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,11292,1,5,0)
 ;;=5^Hodgkin's Lymphoma,Unspec Type & Site
 ;;^UTILITY(U,$J,358.3,11292,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,11293,0)
 ;;=785.6^^69^691^86
 ;;^UTILITY(U,$J,358.3,11293,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11293,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,11293,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,11293,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,11294,0)
 ;;=200.20^^69^691^89
 ;;^UTILITY(U,$J,358.3,11294,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11294,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,11294,1,5,0)
 ;;=5^Lymphoma,Burkett's,Unspecified Sites
 ;;^UTILITY(U,$J,358.3,11294,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,11295,0)
 ;;=202.00^^69^691^88
 ;;^UTILITY(U,$J,358.3,11295,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11295,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,11295,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,11295,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,11296,0)
 ;;=200.10^^69^691^87
 ;;^UTILITY(U,$J,358.3,11296,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11296,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,11296,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,11296,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,11297,0)
 ;;=273.3^^69^691^90
 ;;^UTILITY(U,$J,358.3,11297,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11297,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,11297,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,11297,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,11298,0)
 ;;=203.00^^69^691^99
 ;;^UTILITY(U,$J,358.3,11298,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11298,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,11298,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,11298,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,11299,0)
 ;;=203.01^^69^691^98
 ;;^UTILITY(U,$J,358.3,11299,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11299,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,11299,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,11299,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,11300,0)
 ;;=238.6^^69^691^102
 ;;^UTILITY(U,$J,358.3,11300,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11300,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,11300,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,11300,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,11301,0)
 ;;=205.00^^69^691^5
 ;;^UTILITY(U,$J,358.3,11301,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11301,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,11301,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,11301,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,11302,0)
 ;;=205.01^^69^691^4
 ;;^UTILITY(U,$J,358.3,11302,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11302,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,11302,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,11302,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,11303,0)
 ;;=205.10^^69^691^29
 ;;^UTILITY(U,$J,358.3,11303,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11303,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,11303,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,11303,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,11304,0)
 ;;=205.11^^69^691^28
 ;;^UTILITY(U,$J,358.3,11304,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11304,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,11304,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,11304,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,11305,0)
 ;;=289.0^^69^691^52
 ;;^UTILITY(U,$J,358.3,11305,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11305,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,11305,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,11305,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,11306,0)
 ;;=238.4^^69^691^103
 ;;^UTILITY(U,$J,358.3,11306,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11306,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,11306,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,11306,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,11307,0)
 ;;=V58.61^^69^691^124
 ;;^UTILITY(U,$J,358.3,11307,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11307,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,11307,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,11307,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,11308,0)
 ;;=282.49^^69^691^116
 ;;^UTILITY(U,$J,358.3,11308,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11308,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,11308,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,11308,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,11309,0)
 ;;=289.89^^69^691^18
 ;;^UTILITY(U,$J,358.3,11309,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11309,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,11309,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,11309,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,11310,0)
 ;;=238.79^^69^691^85
 ;;^UTILITY(U,$J,358.3,11310,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11310,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,11310,1,5,0)
 ;;=5^Lymph/Hematpoietc Tis NEC
 ;;^UTILITY(U,$J,358.3,11310,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,11311,0)
 ;;=287.30^^69^691^104
 ;;^UTILITY(U,$J,358.3,11311,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11311,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,11311,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,11311,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,11312,0)
 ;;=288.09^^69^691^8
 ;;^UTILITY(U,$J,358.3,11312,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11312,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,11312,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,11312,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,11313,0)
 ;;=284.81^^69^691^15
 ;;^UTILITY(U,$J,358.3,11313,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11313,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,11313,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,11313,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,11314,0)
 ;;=284.89^^69^691^14
 ;;^UTILITY(U,$J,358.3,11314,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11314,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,11314,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,11314,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,11315,0)
 ;;=284.9^^69^691^12
 ;;^UTILITY(U,$J,358.3,11315,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11315,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,11315,1,5,0)
 ;;=5^Aplastic Anemia NOS
 ;;^UTILITY(U,$J,358.3,11315,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,11316,0)
 ;;=289.84^^69^691^117
 ;;^UTILITY(U,$J,358.3,11316,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11316,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,11316,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,11316,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,11317,0)
 ;;=204.02^^69^691^3
 ;;^UTILITY(U,$J,358.3,11317,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11317,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,11317,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,11317,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,11318,0)
 ;;=204.12^^69^691^25
 ;;^UTILITY(U,$J,358.3,11318,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11318,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,11318,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,11318,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,11319,0)
 ;;=204.21^^69^691^112
 ;;^UTILITY(U,$J,358.3,11319,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11319,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,11319,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,11319,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,11320,0)
 ;;=204.20^^69^691^113
 ;;^UTILITY(U,$J,358.3,11320,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11320,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,11320,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,11320,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,11321,0)
 ;;=204.22^^69^691^114
 ;;^UTILITY(U,$J,358.3,11321,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11321,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,11321,1,5,0)
 ;;=5^Subacute LL, in Relapse
 ;;^UTILITY(U,$J,358.3,11321,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,11322,0)
 ;;=203.02^^69^691^100
 ;;^UTILITY(U,$J,358.3,11322,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11322,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,11322,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,11322,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,11323,0)
 ;;=205.02^^69^691^6
 ;;^UTILITY(U,$J,358.3,11323,1,0)
 ;;=^358.31IA^5^2
